Ignite Creation Date:
2024-05-06 @ 5:07 PM
Last Modification Date:
2024-10-26 @ 2:22 PM
Study NCT ID:
NCT05193591
Status:
RECRUITING
Last Update Posted:
2023-08-07
First Post:
2021-12-02
Brief Title:
Anti-C1s Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus DYSALARM-322
Sponsor:
University Hospital Grenoble
Organization:
University Hospital Grenoble
Study Overview
Official Title:
Evaluation of Anti-C1s Anti-HMGB1 and Anti-C1q Autoantibodies in the Pathogenesis for Patients With Systemic Lupus Erythematosus SLE
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DYSALARM-322
Brief Summary:
Systemic lupus erythematosus SLE is a chronic autoimmune disease characterized by the production of multiple autoantibodies and accumulation of immune complexes resulting in systemic inflammatory response and tissue damage
Dysfunction of proteins initially known to initiate the classical pathway for complement activation C1q and C1s and their functional interference with the multifunctional protein HMGB1 High-Mobility Group Box 1 appears to be associated with SLE On the other hand C1s HMGB1 and C1q can be targeted by anti-C1s anti-HMGB1 and anti-C1q autoantibodies from lupus patients whose functional impact remains to be explored in particular for non-canonical functions independent of the complement activation cascade
Studies are needed to investigate the pathogenic role of these autoantibodies in SLE including possible interference with the inactivation of HMGB1
This project plans to investigate the role of anti-C1s anti-HMGB1 and anti-C1q autoantibodies in the pathogenesis of Systemic Lupus Erythematosus This pilot study will be performed for 30 patients with active SLE on serum realized for routine patient care The investigators will identify the molecular targets recognized by anti-C1s anti-HMGB1 and anti-C1q autoantibodies purified from the SLE patients serum The investigators will also explore the functional role of these purified autoantibodies
Dysfunction of proteins initially known to initiate the classical pathway for complement activation C1q and C1s and their functional interference with the multifunctional protein HMGB1 High-Mobility Group Box 1 appears to be associated with SLE On the other hand C1s HMGB1 and C1q can be targeted by anti-C1s anti-HMGB1 and anti-C1q autoantibodies from lupus patients whose functional impact remains to be explored in particular for non-canonical functions independent of the complement activation cascade
Studies are needed to investigate the pathogenic role of these autoantibodies in SLE including possible interference with the inactivation of HMGB1
This project plans to investigate the role of anti-C1s anti-HMGB1 and anti-C1q autoantibodies in the pathogenesis of Systemic Lupus Erythematosus This pilot study will be performed for 30 patients with active SLE on serum realized for routine patient care The investigators will identify the molecular targets recognized by anti-C1s anti-HMGB1 and anti-C1q autoantibodies purified from the SLE patients serum The investigators will also explore the functional role of these purified autoantibodies
Detailed Description:
Regarding the exploration of anti-C1s autoantibodies purified from the SLE patients serum the investigators will evaluate their effects on the formation of the C1r2C1s2 tetramer and interaction with C1q and their effects on the esterase activity of C1s
Regarding the exploration of anti-HMGB1 autoantibodies purified from the SLE patients serum the investigators will evaluate their effects on the binding of HMGB1 to its RAGE receptor and their effects on the binding of HMGB1 to C1q
Regarding the exploration of anti-C1q autoantibodies purified from the SLE patients serum the investigators will evaluate their effects on the binding of C1q to its receptors and to the C1r2C1s2 tetramer and their effects on the activation of the classical Complement pathway
Regarding the exploration of anti-HMGB1 autoantibodies purified from the SLE patients serum the investigators will evaluate their effects on the binding of HMGB1 to its RAGE receptor and their effects on the binding of HMGB1 to C1q
Regarding the exploration of anti-C1q autoantibodies purified from the SLE patients serum the investigators will evaluate their effects on the binding of C1q to its receptors and to the C1r2C1s2 tetramer and their effects on the activation of the classical Complement pathway
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2021-A02672-39 | OTHER | ID RCB | None |